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This study was designed to compare the bronchodilatatory effect of terbutaline inhaled through 
Turbuhaler@ (TH) or pressurized metered-dose inhaler (pMD1) in young asthmatics, and to assess the 
possible relationship between patients’ inspiratory capacity and bronchodilatation for both devices. 
One hundred and eighteen asthmatics (aged 4 10/12-20 6/12 years) with bronchial obstruction (mean 
vmax 50%: 59.5%,,,,,, sD 17.8%,,,,,) were allocated at random to two groups of 59 patients to inhale 
0.5 mg terbutaline either by TH or by pMD1 (and placebo by dummy of the other device). In- and 
expiratory spirometry and bodyplethysmography were conducted before and 10 min after inhalation. 
Bronchodilatation was effective [change in airways resistance (AR,,) - 50%, change in forced 
expiratory volume in 1 s (AFEV,) + 15%, A pmax 50% or 25% +25% of baseline] in 41 of 59 patients with 
pMD1 (69.5%) and 33 of 59 patients with TH (55.9%). The effect on pmax 50% was significantly better 
with pMD1 than with TH. Turbuhaler@ users with higher inspiratory flow [forced inspiratory volume in 
1 s (FIV,), forced inspiratory flow at 50% vital capacity (FIF&] reached better bronchodilatation, while 
bronchodilatatory effect was not correlated with inspiratory performance in MD1 users. Peak inspiratory 
flow (PIF) did not correlate well with bronchodilatation by TH. 
When using TH for bronchodilatation, the effectiveness of terbutaline depends upon the degree of 
inspiratory capacity. This can lead to impaired bronchodilatatory effect in subgroups of obstructive 
young asthmatics with low inspiratory flow. In contrast, when using a pMD1, inspiratory capacity does 
not seem to influence the effectiveness of terbutaline. 
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Introduction 
Sufficient bronchodilatation can be achieved by 
pressurized metered-dose inhalers (pMD1) with 
low inspiratory flow (l), because drug particle 
diameters depend on the physicochemical prop- 
erties of the drug-additive mixture (2), but 
not on inspiratory flow. In contrast, in the 
Turbuhaler@ (TH), insp’ oratory flow produces 
respirable particles by sucking large drug 
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particles with turbulent airstream into an inha- 
lation channel, where the particles break up 
(2,3). It has been shown that the proportion of 
respirable particles of budesonide (4) and the 
lung deposition of budesonide and terbutaline 
(4,5) can be improved by increasing inspisatory 
flow from about 30 to 60 1 min - 1 (peak flow 
through TH, PIF-TH). 
Despite these results, Pedersen et al. (6) found 
the same bronchodilatatory effect of terbutaline 
with a PIF-TH of 31 and 60 1 min - ‘, Newman 
et al. (5), however, reported a non-significant 
lower effect with 28 compared to 57 1 min ~ I. 
The majority of children reach a PIF-TH in 
the critical range between 30 and 60 I min - ’ (6). 
It is conceivable that those with ins 
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in the lower end of this range profit less from 
bronchodilatation by TH compared to pMD1. 
In two studies (7,8) with 12 and 13 asthmatic 
children, respectively, a 15% rise of forced 
expiratory volume in 1 s (FEV,) was reached 
with pMDI and TH without a significant differ- 
ence, but the finding that a certain threshold can 
be reached does not exclude gradual differences 
in the effect, which might be flow-dependent 
with TH, but perhaps not with pMD1. 
The main aim of the following double-blind, 
double-dummy, placebo-controlled trial was to 
compare the effect of terbutaline inhaled through 
TH or pMD1 on lung function. A secondary aim 
was to evaluate the relationship between the 
inspiratory capacity of young asthmatics and the 
effect of terbutaline upon bronchodilatation for 
both devices. In addition to PIF, the authors 
determined the forced inspiratory flow at 50% 
vital capacity (FIF,,) and the forced inspiratory 
volume in the first second of inspiration (FIV,), 
which may correspond better with the entire 
inhalation manoeuvre, especially in children 
with irregular inhalation technique. 
Methods 
One hundred and eighteen consecutive young 
asthmatic patients (aged 4 10/12-20 6/12 years) 
who attended the authors’ outpatient depart- 
ment with acute bronchial obstruction [ l?max 
25%, FEV, ~70% pred., airways resistance 
(RAW) > 150% pred.] and had not used 
&-agonists in the preceding hours (short-acting 
agonists, 3 h; long-acting agonists, 8 h) were 
allocated at random to inhale 0.5 mg terbutaline 
either by TH or by pMD1 without spacer (and 
placebo by dummy of the other device). The 
pMD1 and TH groups both included 59 patients 
and did not differ significantly in demographic 
and clinical characteristics, and baseline pul- 
monary function except thoracic gas volume 
(TGV) (pMDI>TH, P=O*O5) (Tables l-3). 
Forced and deep inspiration through TH and 
through pneumotachograph was demonstrated 
by experienced nurses before the measurements 
were taken. Emphasis was put on uniformity of 
manoeuvres during drug inhalation and spirom- 
etry. Only four TH patients had used a TH 
previously. 
Immediately before and 10 min after inha- 
lation, in- and expiratory spirometry and 
bodyplethysmography (pneumotachograph and 
MasterLab@-bodyplethysmograph, Jaeger 




Age (mean; SD in months) 140; 43 135;.38 
Height (mean; SD in cm) 149; 18 145; 17 
Gender (female/male) 19140 26133 
Grade of severity (I/II/III)* 3112414 3312016 
Need for inhalative steroids (n) 25 25 
pMD1, pressurized metered-dose inhaler; TH 
Turbuhaler@; SD, standard deviation. 
*According to ‘Deutsche Atemwegsliga 1994’ (9), 
symptom frequency: Grade 1 <l/month; Grade II 
<l/week; Grade III >I= l/week. 
TABLE 2. Baseline pulmonary function of 118 patients 
pMD1 (n = 59) (nZ9) 
timax 50% 1 s - ‘) 1.96 (0.69) 1.93 (0.92) 
pmax 50% (% pred.“) 59.4 (16.6) 59.7 (19.3) 
FEV, (1) 2.05 (0.71) 1.91 (0.78) 
FEV, (% pred.“) 85.9 (15.2) 84.7 (16.1) 
vein Cl) 2.68 (1.00) 2.47 (1.03) 
VC;, (% pred.“) 92.1 (12.5) 90.1 (15.1) 
pMD1, pressurized metered-dose inhaler; TH, 
Turbuhaler@. 
Values are mean (standard deviation) values. 
*According to Zapletal et al. (10). 
TABLE 3. Inspiratory performance of 118 patients 
pMD1 
(n=59) (nZ9) 
PIF (1 min - ‘)* 164.9 (75.6) 162.9 (71.7) 
FIF,, (1 s - ‘)* 2.44 (1.21) 2.45 (1.14) 
FIV, (l)* 1.96 (0.85) 1.87 (0.80) 
pMD1, pressurized metered-dose inhaler; TH, 
Turbuhaler@. 
All values are mean (standard deviation) values. 
*Inspiration without inhalation device. 
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TABLE 4. Bronchodilatation with 0.5 mg terbutaline by pressurized metered-dose inhaler 
(pMD1) or Turbuhaler@ (TH) 
pMDI(n = 59) (?zZ) 
Diff. 
pMD1 - TH 
A tinax,,, (1 s - ‘) 0.64 (05-0.78) 0.44 (0.33-0.54) 0.20 (0.040.37) 
dFEV, (1) 0.29 (0.22-0.35) 0.22 (0.16-0.28) 0.07 ( - 0.02-0.15) 
Columns ‘pMD1’ and ‘TH’, means of differences before and after bronchodilatation; 
Column ‘Diff. pMD1 - TH’, difference of means. 
95% confidence intervals in parentheses. 
GmbH & Co KG, Wiirzburg, Germany) were 
performed. Inspiratory performance was deter- 
mined without the two inhalation devices to 
! 
rP < 0.051 
-0.5 ’ 
I I I 
n = 15 14 16 13 14 17 13 15 
pMD1 TH 
Quartiles of FIV, 
5 0.6-1.26 I ; 1.77-2.461 I 
; 1.27-1.76 I ; 2.47-4.63 I 
FIG. 1. Means of differences in maximal flow at 
50% vital capacity (timax 50%) before and after 
0.5 mg terbutaline ( f SD). dvmax 50% values are 
plotted for quartiles of forced inspiratory volume 
in 1 s (FIV,) ascending from left to right for both 
pressurized metered-dose inhaler (pMD1) and 
Turbuhaler@ (TH) users. Calculation basis for 
quartiles: whole population (pMDI+ TH users, 
n=llS). 
P value indications: significant differences 
between pMD1 and TH groups (t-test, PcO.05) and 
for TH users between patients with FIV, above and 
below median (1.76 1) (t-test, PcO.05). 
n = Number of patients in each quartile (whole- 
population based). For one patient with pMD1, 
dprnax 50% could not be determined because of a 
cough artefact at post-bronchodilatation measure- 
ment. 
allow comparison of its influence on their 
bronchodilatatory effects. 
Effective bronchospasmolysis (BSL) was 
defined as having a minimum change of lung 
function values 10 min after terbutaline inha- 
lation for at least one of the following par- 
ameters: R,, <I= - 50%, FEV,> = + 15%, 
l?max 50 or 25 </= +25%. If sufficient bron- 
chodilatation was not achieved, patients inhaled 
0.4 mg fenoterol by pMD1 and measurements 
were repeated 10 min later to evaluate the 
maximal possible bronchodilatation. 
STATISTICAL ANALYSIS 
Data was fed into the computer twice to check 
for mistakes. SPSS for MS Windows 6.01 was 
used as software for all statistical tests. Metered- 
dose inhaler and TH results were compared with 
Chi-square test (discrete data), Mann-Whitney 
U-test (non-normally distributed continuous 
data) or two sided t-test (normally distributed 
continuous data). Statistical significance was 
assumed at P<O.O5. To assess the relation 
between inspiratory performance and terbutaline 
effect on lung function, a multiple linear regres- 
sion analysis was conducted, and the corre- 
sponding partial correlation coefficients were 
calculated (significance of coefficients: PcO.05, 
two sided). 
Results 
Forty-one of 59 pMD1 patients (69.5%) and 33 
of 59 TH patients (55.9%) reached a significant 
BSL effect with 0.5 mg terbutaline (difference 
not significant). Of the remaining patients, 37 
(14 pMD1, 23 TH) inhaled fenoterol, and seven 
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TABLE 5. Inspiratory flow and terbutaline effect with pressurized metered-dose inhaler 
(pMD1) or Turbuhaler@ (TH) 
FIV, FIF,, PIF 
pMD1 (n = 587): A pmax 50% (1 s - ‘) 
pMD1 (n=59): AFEV, (1) 
TH (n = 59): A pmax 50% (1 s ~ ‘) 
TH (n=59): AFEV, (1) 
0.03 0.09 0.03 
0.01 0.08 0.08 
0.37” 0.18 0.22 
0.28 0.19 0.19 
FIV,, forced inspiratory volume in 1 s; FIF,,, forced inspiratory flow at 50% vital 
capacity; PIF, peak inspiratory flow. 
Each column shows partial correlation coefficients for one of three inspiratory variables 
(FIVr, FIF,,, PIF) and bronchodilatatory effect (A pmax 50% resp. AFEV,), separately for 
pMD1 and TH. 
The correlation coefficients are adjusted for age, height, FEV, (%pred.), VCin (%pred.), 
VCin, RV (%TLC). *P<O.Ol. 
I-For one patient, A pmax 50% could not be determined because of a cough artefact at post 
bronchodilatation measurement. 
TABLE 6. Inspiratory flow and terbutaline effect (in % of fenoterol effect) with pressurized 
metered-dose inhaler (pMD1) or Turbuhaler@ (TH) 
FIV, FIFm PIF 
pMD1 (n= 14): pmax 50% terbutaline (“XI of fenoterol) - 0.28 0.26 - 0.63 
pMD1 (n= 14): FEV, terbutaline (% of fenoterol) - 0.33 - 0.41 - 0.40 
TH (n=23) pmax 50% terbutaline (% of fenoterol) 0.28 0.36 0.33 
TH (n=23): FEV, terbutaline (% of fenoterol) 0.33 0.50” 0.44 
FIV,, forced inspiratory volume in 1 s; FIF,,, forced inspiratory flow at 50% vital 
capacity; PIF, peak inspiratory flow. 
Each column shows partial correlation coefficients for one of three inspiratory variables 
(FIVl, FIF,,, PIF) and relative bronchodilatatory effect (pmax 50% resp. FEV, after 
terbutaline in % of pmax 50% resp. FEV, after fenoterol), separately for pMD1 and TH. 
The correlation coefficients are adjusted for age, height, FEV, (%pred.), VCin (%pred.), 
VCin, RV (%TLC): *P<O.O5. 
pMD1 and 10 TH patients reacted (significantly) 
positively to it. 
The p-MD1 was slightly more effective for 
most indicators of obstruction. The difference 
was statistically significant (BO.05) for A Pmax 
50%. Results for selected parameters are 
presented in Table 4. 
higher inspiratory flow (FIV,) was linearly posi- 
tively related to better bronchodilatation 
(dpmax 50%) in TH patients alone. The regres- 
sion coefficient of A pmax 50% (1 s - ‘) to FIV, (1) 
was 0.71, and the 95% confidence interval (CI) 
ranged from 0.19 to 1.22 (partial correlation 
coefficients, see Table 5). 
The effect of bronchodilatation was greater Thirty-seven patients, who did not reach sig- 
with higher inspiratory flow (FIV, 2 1.77 1) in nificant bronchodilatation with 0.5 mg terbuta- 
TH patients, but not in pMD1 patients (Fig. 1). line, inhaled 0.4 mg fenoterol 10 min later, which 
In the multiple regression, including other fac- was assumed to be the dose necessary to reach 
tors of potential influence on the bronchodilata- the maximal possible bronchodilatation. This 
tory effect [grade of baseline obstruction, subgroup did not differ from the rest of the 
inspiratory vital capacity (VC3, height and age], patients, with the exception of a lower RAW, 
indicating a weaker obstruction at baseline 
(PcO.05). For these patients, the relative terbu- 
taline effect as a percentage of the maximal 
possible (i.e. fenoterol) effect was calculated. 
There was no difference in the relative terbu- 
taline effect between pMD1 and TH users. In 
both groups, lower inspiratory flow was non- 
significantly associated with lower relative terbu- 
taline effect. After considering age, height and 
baseline obstruction, a significant correlation 
between FIF,, and relative terbutaline effect was 
found in TH users alone. The regression coef- 
ficient of FEV, terbutaline (% of fenoterol) 
to FIF,, (1 s - ‘) was 34.53, and the 95% CI 
ranged from 1.64 to 67.42 (partial correlation 
coefficients, see Table 6). 
Discussion 
In this cohort of young outpatient asthmatics, 
bronchodilatation with 0.5 mg terbutaline was 
slightly, but (d pmax 50%) significantly, more 
effective with pMD1 than with TH. Like others 
(7,8), the present authors could not detect a 
difference between pMD1 and TH in terms of the 
number of subjects reaching a certain bronchodi- 
latatory threshold (i.e. a 15% rise of FEV,), but 
a difference was found in the mean effect in 
larger groups, which may be a more sensitive 
means of statistical evaluation. 
Inspiratory capacity, determined by spi- 
rometry without device immediately before 
inhalation, was associated with the bronchospas- 
molytic effect in TH users, but not in pMD1 
users. In children with a FIV, below 1.77 1, mean 
bronchodilatatory effect was significantly lower 
than in those with higher FIV,. 
As the flow during the inhalation manoeuvre 
was not measured, the authors cannot conclude 
that higher inspiratory flow through TH causes 
better bronchodilatation. The authors’ conclu- 
sion is that children with better inspiratory 
capacity inhale terbutaline more effectively 
through the TH than children with weaker 
capacity. In contrast, inspiratory capacity does 
not seem to influence the efficacy of terbutaline 
when using a pMD1. 
The study patients’ FIV, and FIF,, were 
correlated better with the effect of TH use than 
their PIF. Even though flow through TH cannot 
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be predicted accurately from flow without TH 
(II), this may suggest that not only the PIF but 
also the inspiratory flow throughout the entire 
inspiratory range has an impact upon the effect 
of bronchodilatation via TH. This hypothesis 
would explain why some investigators who 
measured only PIF-TH did not find a difference 
in the effect at lower and higher inspiratory flows 
(6). If the relation between inspiratory perform- 
ance and the therapeutic effect of inhalable drugs 
is to be assessed in the future, FIV, and FIF,, 
should be monitored both with and without the 
inhalation devices. 
Although the regression coefficient calculated 
from these data theoretically allows the predic- 
tion of d pmax 50% from FIV,, the wide 95% CI 
indicates that this prediction would be of no 
practical value. Nevertheless, the data suggest 
that a simple spirometric assessment of the 
inspiratory capacity might help to identify 
children less qualified for the use of the TH. 
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